An interventional study of EUS+ERCP and ERCP in Pancreaticobiilary Diseases, sponsored by Qilu Hospital of Shandong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Qilu Hospital of Shandong University · Not applicable, Interventional, and Treatment
This is a single-center randomized controlled trial. Eligible subjects meeting inclusion/exclusion criteria will be randomized 1:1 to EUS+ERCP group or ERCP group. Clinical data and patient-reported outcomes are regularly collected at baseline and during follow-up periods. A comparative analysis was conducted to assess the impact of same-session EUS on ERCP strategy modification between two groups, utilizing a structured questionnaire.Secondarily, the safety and efficacy of same-session EUS will be comprehensively evaluated by comparing complication rates, technical success rate and hospitalization costs, length of stay, and radiation exposure between groups.
Qilu Hospital of Shandong University is the lead sponsor of 299 studies on the registry; 181 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
EUS and ERCP were performed during the same session under continuous sedation/anesthesia in the intervention group.
Procedure: EUS+ERCP
Only ERCP was performed in the control group
Procedure: ERCP
EUS were performed during the same session with ERCP under continuous sedation/anesthesia
Only ERCP was performed in the control group
ERCP strategy modification rate
Concordance rate between anticipated and actual ERCP procedural strategies and the rate of avoiding unnecessary ERCP procedures.
Time frame: From enrollment to 6 months after the end of treatment
Procedure outcomes
Technical success rate (defined as successful completion of intended therapeutic intervention) ERCP procedure time (from duodenoscope insertion to withdrawal) Difficult cannulation rate (requiring advanced techniques or \>5 attempts)
Time frame: From enrollment to 6 months after the end of treatment
Incidence of complications
Time frame: From enrollment to 6 months after the end of treatment
Radiation-related situation
Fluoroscopy time (minutes) Radiation exposure (dose-area product, Gy·cm²)
Time frame: From enrollment to 6 months after the end of treatment
Healthcare utilization measures
Hospital length of stay (days) Total hospitalization costs
Time frame: From enrollment to 6 months after the end of treatment
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qilu Hospital of Shandong University